For those treated with GLP-1 Ras, 2.8% were admitted due to COVID-19, and 1.5% for other reasons, while among the subjects treated with DPP-4 inhibitors (DPP-4is), the respective percentages were 3.6% for COVID-19-related hospitalization and 2.0% for other reasons. This evidence concerns the gene GLP1R and COVID-19.